If you're seeing this message, that means
JavaScript has been disabled on your browser
, please
enable JS
to make this app work.
No tags found
Companies
No companies found
Advanced Search
Newsfeed
Alerts
Saved Lists
Sign Up for Free
Login
Get Updates
147
Followers on Owler
Capricor
is a California-based biotechnology company that develops cell and exosome-based therapeutics for the treatment of novel diseases...
Read more
Overview
Competitors
Funding
News & Insights
Capricor
is a California-based biotechnology company that develops cell and exosome-based therapeutics for the treatment of novel diseases...
Read more
President & CEO
Linda Marban
CEO Approval Rating
90/100
Weigh In
2005
San Diego
California
San Diego County
Public
NASDAQ
CAPR
Pharmaceuticals & Biotechnology
Biotechnology
2836
2834
NAICS listing
https://capricor.com/
Annual Revenue
$22.3M
Employees
101
Funding
$152.5M
News
Latest News
Aug 07, 2026
GlobalNewswire
Press Release: Capricor : ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR
Aug 07, 2026
Benzinga
Capricor: INVESTOR NOTICE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - CAPR
Aug 06, 2026
Vsnewsnetwork
Capricor: Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Aug 06, 2026
GlobalNewswire
Press Release: Capricor : Kaplan Fox Reminds Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 28, 2026
Aug 06, 2026
PR-Inside
Press Release: Capricor : CAPR: Block & Leviton Encourages Capricor Therapeutics Investors to ...
Aug 06, 2026
Nynewsly
Capricor: Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
Aug 06, 2026
Benzinga
Capricor: CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Aug 05, 2026
Benzinga
Capricor: Levi & Korsinsky Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR
Aug 05, 2026
Financialcontent
Capricor: Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws
Aug 04, 2026
Benzinga
Capricor: CAPR INVESTOR NOTICE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Capricor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Follow and Get Alerts
Capricor Competitors
1
Follow
2
Follow
3
Follow
4
Follow
5
Follow
6
Follow
7
Follow
8
Follow
9
Follow
10
Follow
Unlock 22 + competitors
Trending Companies